Topica Pharmaceuticals

Topica began its life with a promising novel anti-fungal called luliconazole (Lulicon) in hand. The compound was developed by Nihon Nohyaku and is already approved in Japan for tinea infections. Topica's initial focus will be on advancing ongoing clinical trials of the drug in athlete's foot, but even as it begins studies in athlete's foot, a market IMS estimates to be approximately $400 million in the US alone, the end goal is a topical treatment for onychomycosis.